Metabolic
Survodutide
Also called BI 456906
per administration
A human trial worked out how much to take and how often, so a dosing schedule is shown.
Quick start
Survodutide at a glance — the figures, plus how it's commonly run. Reference only, not medical advice.
- Typical dose
- 0.6–4.8 mg per administration
- How often
- Once a week
- Where
- Subcutaneous — abdomen, thigh, or upper arm Sites and rotation
- Time to steady level
- ~30.0 days — about five half-lives
- Storage
- Dry vial kept cold and dark; a mixed vial in the fridge at 2–8 °C. Details
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
Work out your draw
These numbers are a starting point — change any of them.
Vial label
Copy this into your label printer.
Published research contexts for Survodutide describe 0.6–4.8 mg per administration. Descriptive only, not a recommendation.
About 6 days, with high albumin binding; supports once-weekly dosing.
Dosing schedule
How Survodutide is commonly stepped up, for reference only.
These are commonly-discussed research protocols shared for educational reference. This is not medical advice and is not a substitute for guidance from a qualified professional.
| Phase | Amount | Frequency | Route |
|---|---|---|---|
| Weeks 1–4Lowest maintenance arm and the starting step; escalation limits gastrointestinal load. | 0.6 mg | Once weekly | SubQ |
| Step up | 2.4 mg | Once weekly | SubQ |
| Step up | 3.6 mg | Once weekly | SubQ |
| Highest armHighest maintenance in the phase-2 trial; reached by stepwise titration only as tolerated. | 4.8 mg | Once weekly | SubQ |
Modelled level — once a week
1× is the peak after a single dose.
- Steady-state peak
- 1.74× single dose
- Time to steady state
- 30.0days
- Administrations
- 1/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- le Roux CW et al., Lancet Diabetes Endocrinol 2024;12:162Phase-2 dose-finding of the GLP-1/glucagon dual agonist survodutide; weekly maintenance arms of 0.6, 2.4, 3.6 and 4.8 mg over 46 weeks in adults with obesity.